The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.

Including the name of the #1 company to buy.

Owen Witte Biography and Net Worth

Director of Allogene Therapeutics

Dr. Owen N. Witte, M.D. serves as Independent Director of the Company. Dr. Witte previously served as a member of the board of directors of Kite Pharma, Inc. (“Kite”) from March 2017 until October 2017. Dr. Witte joined the UCLA faculty in 1980, where he is presently a University Professor of microbiology, immunology and molecular genetics, the UCLA David Saxon Presidential Chair in Developmental Immunology and the director of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research. Dr. Witte was appointed a University Professor by the University of California Board of Regents, an honor reserved for scholars of the highest international distinction. Dr. Witte is a member of the National Academy of Sciences, the American Academy of Arts and Sciences, and the National Academy of Medicine. Dr. Witte currently serves on several editorial and advisory boards. He previously served on the board of directors for the American Association for Cancer Research. He was appointed by President Obama to the President’s Cancer Panel. Dr. Witte holds a bachelor’s degree from Cornell University and an M.D. from Stanford University. He completed postdoctoral research at the Massachusetts Institute of Technology.

What is Owen N. Witte's net worth?: The estimated net worth of Owen N. Witte is at least $493,428.91 as of August 11th, 2022. Dr. Witte owns 223,271 shares of Allogene Therapeutics stock worth more than $493,429 as of November 23rd. This net worth approximation does not reflect any other investments that Dr. Witte may own. Learn More about Owen N. Witte's net worth.
How do I contact Owen N. Witte?: The corporate mailing address for Dr. Witte and other Allogene Therapeutics executives is 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. Allogene Therapeutics can also be reached via phone at (650) 457-2700 and via email at [email protected]. Learn More on Owen N. Witte's contact information.
Has Owen N. Witte been buying or selling shares of Allogene Therapeutics?: Owen N. Witte has not been actively trading shares of Allogene Therapeutics within the last three months. Most recently, Owen N. Witte sold 10,000 shares of the business's stock in a transaction on Thursday, August 11th. The shares were sold at an average price of $16.50, for a transaction totalling $165,000.00. Following the completion of the sale, the director now directly owns 223,271 shares of the company's stock, valued at $3,683,971.50. Learn More on Owen N. Witte's trading history.
Who are Allogene Therapeutics' active insiders?: Allogene Therapeutics' insider roster includes Rafael Amado (CMO), Arie Belldegrun (Director), Veer Bhavnagri (General Counsel), and Owen Witte (Director). Learn More on Allogene Therapeutics' active insiders.
Are insiders buying or selling shares of Allogene Therapeutics?: During the last year, Allogene Therapeutics insiders bought shares 2 times. They purchased a total of 1,724,327 shares worth more than $5,000,681.30. During the last year, insiders at the sold shares 2 times. They sold a total of 29,840 shares worth more than $76,536.00. The most recent insider tranaction occured on May, 30th when Director Franz B Humer sold 11,200 shares worth more than $26,208.00. Insiders at Allogene Therapeutics own 24.3% of the company. Learn More about insider trades at Allogene Therapeutics.
Information on this page was last updated on 5/30/2024.

Owen N. Witte Insider Trading History at Allogene Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/11/2022	Sell	10,000	$16.50	$165,000.00	223,271
6/22/2022	Sell	10,000	$11.76	$117,600.00	233,271
9/9/2021	Sell	5,000	$25.54	$127,700.00	221,182
8/20/2021	Sell	10,000	$23.47	$234,700.00
6/9/2021	Sell	9,969	$25.05	$249,723.45	236,182

Owen N. Witte Buying and Selling Activity at Allogene Therapeutics

Allogene Therapeutics Company Overview

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Today's Range

Now: $2.21

$2.09

$2.23

50 Day Range

MA: $2.69

$2.05

$3.22

2 Week Range

Now: $2.21

$1.99

$5.78

Volume

1,416,891 shs

Average Volume

2,660,311 shs

Market Capitalization

$463.37 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.84

Financial Prophecy

From Porter & Company | Ad